September 3, 2025

Breakthrough in mitochondria therapy: CSEM and cellvie automate isolation process for clinical use

  • The developed platform brings mitochondria transplantation treatment for ischemia-reperfusion injury one step closer to patients
  • cellvie and CSEM joined forces to design a new automated solution to streamline and standardize the manufacturing process.
  • The system is GMP-compliant and ready to transfer to a Contract Development and Manufacturing Organization (CDMO) for Phase I trials.
(Left to Right) A. Schueller, Founder and CEO; This Egloff, Scientist (cellvie); Charlotte Fonta, Senior R&D Engineer; and Gilles Weder, Head R&BD, Life Science Technologies, CSEM.
© CSEM - (Left to Right) Alexander Schueller, Founder and CEO; This Egloff, Scientist (cellvie); Charlotte Fonta, Senior R&D Engineer; and Gilles Weder, Head R&BD, Life Science Technologies (CSEM).

Additional information

CSEM

Gilles Weder
Head R&BD, Life Science Technologies
Telephone +41 79 361 50 12
media@csem.ch

cellvie

Alexander Schueller
Founder and CEO
Telephone +41 44 591 89 21
contact@cellvie.bio

(Left to Right) A. Schueller, Founder and CEO; This Egloff, Scientist (cellvie); Charlotte Fonta, Senior R&D Engineer; and Gilles Weder, Head R&BD, Life Science Technologies, CSEM.
Download

Related Press

Group of 7 persons, members of the CSEM and the TheraMe teams

23 January 2025

CSEM and TheraMe! revolutionize cancer therapy with personalized drug screening technology

What if there was a solution allowing to test which drug or drug combination works best on the tumor cells of a given patient at any given stage of the disease?...

A hand holding a bioreactor to grow vein grafts developed by CSEM and ClexBio

22 February 2024

CSEM and ClexBio create a bioreactor for tissue-engineered cardiovascular implants

The teams at CSEM and at ClexBio have developed a process for engineering vein grafts comprised of human tissue material that integrates into the patient’s body and can turn into real, living tissue....

Limula team

3 February 2023

Making personalized cancer therapies accessible to all

CSEM has supported Lausanne-based start-up Limula in its mission to make cell therapies more affordable, and to facilitate access to these personalized treatments. ...